You are using an outdated browser. Please upgrade your browser to improve your experience.

ibrutinib

Ligand Summary
Ligand Structure
Rendered image for the query structure
Description
Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.
Synonyms & Links
Guide to Pharmacology: 6912
DrugCentral: 4810
LyCHI:  8GKRMF7RW153


Target Activities